San Francisco startup Structure Therapeutics can be working on an oral, once-day by day GLP-one drug referred to as GSBR-1290—the drug surpassed Wall Street’s expectations in June any time a mid-phase examine confirmed typical weight loss of around six% and it plans to begin One more